Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL

Acute myeloid leukemia (AML) patients with minimal residual disease and receiving allogeneic hematopoietic stem cell transplantation (HCT) have poor survival. Adoptive administration of dendritic cells (DCs) presenting the Wilms tumor protein 1 (WT1) leukemia-associated antigen can potentially stimu...

Full description

Bibliographic Details
Main Authors: Julia K. Bialek-Waldmann, Sabine Domning, Ruth Esser, Wolfgang Glienke, Mira Mertens, Krasimira Aleksandrova, Lubomir Arseniev, Suresh Kumar, Andreas Schneider, Johannes Koenig, Sebastian J. Theobald, Hsin-Chieh Tsay, Angela D.A. Cornelius, Agnes Bonifacius, Britta Eiz-Vesper, Constanca Figueiredo, Dirk Schaudien, Steven R. Talbot, Andre Bleich, Loukia M. Spineli, Constantin von Kaisenberg, Caren Clark, Rainer Blasczyk, Michael Heuser, Arnold Ganser, Ulrike Köhl, Farzin Farzaneh, Renata Stripecke
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
WT1
Online Access:http://www.sciencedirect.com/science/article/pii/S232905012100070X